RxDoctor Payments Data

Michael Anderson, MD

Family Medicine · Midwest City, OKNPI 1346226164

Payments from drug & device makers

$9,448in general payments, 2019–2025

Across 592 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$778
  • Pfizer$366
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$9,35699%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,448 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$118,910
Medicare patients
205
Services billed
2,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol36$31,326
OzempicSemaglutide23$31,050
MounjaroTirzepatide14$26,495
JanuviaSitagliptin Phosphate12$20,966
JardianceEmpagliflozin14$19,386
MyrbetriqMirabegron16$15,679
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,649
LinzessLinaclotide15$12,640
TrulicityDulaglutide11$7,206
Raloxifene Hcl71$3,643
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,633
Rosuvastatin Calcium161$2,314
Levothyroxine Sodium129$1,611
Albuterol Sulfate HfaAlbuterol Sulfate49$1,267
Atorvastatin Calcium121$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,743$46,97551 claims
Lilly USA, LLCMounjaro, Trulicity$1,128$33,70125 claims
Novo NordiskOzempic$1,024$31,05023 claims
MerckJanuvia$213$20,96612 claims
Boehringer IngelheimJardiance$778$19,38614 claims
Astellas Pharma US IncMyrbetriq$178$15,67916 claims
AbbVieLinzess, Synthroid$1,264$13,41733 claims
GSKShingrix$338$2,63312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →